Catalyst

Slingshot members are tracking this event:

Zogenix (ZGNX) Expects Results From Phase 3 Study 1502 Evaluating ZX008 in Dravet Syndrome in Q1 2017

Source Link:
http://seekingalpha.com/article/3957577-zogenixs-zgnx-ceo-steve-farr-q4-2015-results-earnings-call-transcript?part=single

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ZGNX
100%
GWPH
100%
SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Clinical Data A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome
https://clinicaltria...
Additional Relevant Details ZX008
http://www.zogenix.c...
Slingshot Insights Explained
JOIN FOR FREE TODAY
Catalyst Date
Occurred on:
May 25, 2017
Occurred Source:
http://www.nejm.org/doi/full/10.1056/NEJMoa1611618
Related Projects Image

  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3, Study 1502, Results, Zx008, Dravet Syndrome
About Us
Media Center
Connect with Us
© 2024 Slingshot Insights. All rights reserved.